Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by GlobeNewswire

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
99 100 Next >
Blue Max Trucking Selects TruckIT to Optimize Dispatching, E-Ticketing, and Fleet Management for its Heavy Haul Fleet
From TruckIT
Via GlobeNewswire
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
Digital Express Announces Acquisition of Canon varioPRINT iX Inkjet Press
From thINK
Via GlobeNewswire
Newly Announced Royalton Chic Barbados to Join Marriott’s Autograph Collection Portfolio
From Blue Diamond Resorts
Via GlobeNewswire
Crown Announces Suspension of Equity Line of Credit
From Crown Electrokinetics Corp.
Via GlobeNewswire
Tickers CRKN
Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920
From Tevogen Bio Inc
Via GlobeNewswire
Tickers MSFT TVGN TVGNW
CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma Activity
From Cargo Therapeutics, Inc.
Via GlobeNewswire
Tickers CRGX
Malizia-Seaexplorer competing in Vendée Globe under Monaco flag
From Yacht Club de Monaco
Via GlobeNewswire
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma
From Legend Biotech USA Inc.
Via GlobeNewswire
Tickers LEGN
METAGENOMI (NASDAQ: MGX) INVESTOR ALERT: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action
From Berger Montague
Via GlobeNewswire
Tickers MGX
Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
Tickers IPSC
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Turnstone Biologics Corp.
Via GlobeNewswire
Tickers TSBX
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Pacific Eye Associates Selects Nextech
From Nextech Systems, Inc.
Via GlobeNewswire
Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma
From Kronos Bio, Inc.
Via GlobeNewswire
Tickers KRON
Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting
From Century Therapeutics, Inc.
Via GlobeNewswire
Tickers IPSC
Ichnos Glenmark Innovation (IGI) Announces First Presentation of Data from Phase 1 Study of the Trispecific ISB 2001 in Relapsed/Refractory Multiple Myeloma (r/rMM) at Upcoming ASH Annual Meeting
From Ichnos Glenmark Innovation
Via GlobeNewswire
Pangea Launches Two New Advanced Materials
From Pangea
Via GlobeNewswire
Disc Medicine Announces Multiple Presentations Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting
From Disc Medicine Inc
Via GlobeNewswire
Tickers IRON
ImCheck to Present Updated Data from the EVICTION Trial at the 39th Annual Meeting of the Society for Immunotherapy of Cancer
From ImCheck Therapeutics SAS
Via GlobeNewswire
John Snyder, Former BCD CEO and Travel Industry Leader, Joins Oversee’s Advisory Board
From Oversee
Via GlobeNewswire
Kaiser Aluminum Corporation to Participate in Baird’s 2024 Global Industrial Conference
From Kaiser Aluminum Corporation
Via GlobeNewswire
Tickers KALU
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
PrognomiQ Announces $34 Million Series D Financing to Advance Development of Early Detection Test for Lung Cancer with Multi-omics Platform
From PrognomiQ
Via GlobeNewswire
Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
PRIDE Industries Achieves AS9100 Certification, Strengthening its Position in Aerospace and Defense Manufacturing
From PRIDE Industries
Via GlobeNewswire
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.